460-04-013 ISMRM Abstract

Restricted Spectrum Imaging for Automating Tumor Delineation on Serial DWI in Evaluating Breast Cancer Treatment Response

Primary: Body - Breast

Secondary: Diffusion - Diffusion Modeling

460-04-013 · Breast MRI Sequences and Clinical Developments · Tuesday, 12 May, 2:35 PM–3:30 PM · Digital Posters Row A

Keywords: Segmentation Breast cancer Neoadjuvant therapy Diffusion-weighted MRI Restriction spectrum imaging (RSI)

Accepted

Debosmita Biswas ^1,2, Asha R Viswanathan², Yin Guo³, Habib Rahbar³, James H Holmes⁴, Wei Huang^5,6, Savannah Partridge^1,2

¹Radiology, University of Washington, Seattle, United States of America

²Bioengineering, University of Washington, Seattle, United States of America

³University of Washington, Seattle, United States of America

⁴University of Iowa, Iowa City, United States of America

⁵Corewell Health, Detroit, United States of America

⁶Radiation Oncology, Corewell Health, Detroit, United States of America

Presenting Author: Debosmita Biswas

Synopsis

Motivation:

Goals:

Approach:

Results:

Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

References

1. Partridge SC, Zhang Z, Newitt DC, Gibbs JE, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Romanoff J, Cimino L, Joe BN, Umphrey HR, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis JS, Esserman LJ, Hylton NM; ACRIN 6698 Trial Team and I-SPY 2 Trial Investigators. Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial. Radiology. 2018 Dec;289(3):618-627. doi: 10.1148/radiol.2018180273. Epub 2018 Sep 4. PMID: 30179110; PMCID: PMC6283325. [doi] [pmid]

2. Besser AH, Fang LK, Tong MW, Andreassen MMS, Ojeda-Fournier H, Conlin CC, Loubrie S, Seibert TM, Hahn ME, Kuperman JM, Wallace AM, Dale AM, Rodríguez-Soto AE, Rakow-Penner RA. Tri-Compartmental Restriction Spectrum Imaging Breast Model Distinguishes Malignant Lesions from Benign Lesions and Healthy Tissue on Diffusion-Weighted Imaging. Cancers (Basel). 2022 Jun 30;14(13):3200. doi: 10.3390/cancers14133200. PMID: 35804972; PMCID: PMC9264763 [doi] [pmid]

3. Moloney B, Li X, Hirano M, Saad Eddin A, Lim JY, Biswas D, Kazerouni AS, Tudorica A, Li I, Bryant ML, Wille C, Pyle C, Rahbar H, Hsieh SK, Rice-Stitt TL, Dintzis SM, Bashir A, Hobbs E, Zimmer A, Specht JM, Phadke S, Fleege N, Holmes JH, Partridge SC, Huang W. Initial experience in implementing quantitative DCE-MRI to predict breast cancer therapy response in a multi-center and multi-vendor platform setting. Front Oncol. 2024 Nov 29;14:1395502. doi: 10.3389/fonc.2024.1395502. PMID: 39678499; PMCID: PMC11638047. [doi] [pmid]

4. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026. PMID: 19097774. [doi] [pmid]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/460-04-013